|1.||Horváth, Ervin: 3 articles (10/2003 - 07/2002)|
|2.||Mauler, Frank: 3 articles (10/2003 - 07/2002)|
|3.||De Vry, Jean: 2 articles (01/2003 - 07/2002)|
|4.||Hinz, Volker: 1 article (10/2003)|
|5.||Augstein, Karl Heinz: 1 article (10/2003)|
|6.||Fassbender, Marion: 1 article (10/2003)|
|7.||Schwarz, Thomas: 1 article (01/2003)|
|8.||Böttcher, Michael: 1 article (01/2003)|
|9.||Heinig, Roland: 1 article (01/2003)|
|10.||Weinz, Corinna: 1 article (01/2003)|
|1.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
|2.||Brain Edema (Cerebral Edema)
10/31/2003 - "Further, we continued to investigate the neuroprotective properties of BAY 38-7271 in the rat SDH and transient middle cerebral artery occlusion (tMCA-O) model as well as the efficacy with respect to SDH-induced brain edema. "
10/31/2003 - "Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271."
|3.||Brain Injuries (Brain Injury)
07/01/2002 - "In the rat traumatic brain injury model, BAY 38-7271 demonstrated highly potent and efficient neuroprotective properties when administered as a 4-h infusion immediately after induction of subdural hematoma (70% infarct volume reduction at 100 ng/kg/h). "
01/01/2003 - "Recently BAY 38-7271 has been characterized as a structurally novel, selective and highly potent cannabinoid CB1/CB2 receptor agonist in vitro and in vivo with pronounced neuroprotective efficacy in a rat traumatic brain injury model, showing a therapeutic window of at least 5 h. "
01/01/2003 - "BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury."
10/31/2003 - "BAY 38-7271 is a new high-affinity cannabinoid receptor agonist with strong neuroprotective efficacy in a rat model of traumatic brain injury (acute subdural hematoma, SDH). "
|4.||Brain Ischemia (Cerebral Ischemia)
01/01/2003 - "As the doses of BAY 38-7271 in animals needed for maximal neuroprotective efficacy were significantly lower than those inducing typical cannabinoid-like side effects, it is to be expected that the compound will offer a novel therapeutic approach with a favorable therapeutic window for the treatment of TBI or cerebral ischemia."
07/01/2002 - "The neuroprotective potential of BAY 38-7271 was confirmed in a rat model of focal cerebral ischemia induced by permanent occlusion of the middle cerebral artery. "
|5.||Acute Subdural Hematoma
|1.||Cannabinoid Receptors (Cannabinoid Receptor)
|2.||CB2 Cannabinoid Receptor